Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome - Wikidata - awgldk - TriplyDB

Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome

Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome

http://www.wikidata.org/entity/Q24650472

about

Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)How I treat autoimmune lymphoproliferative syndrome Approaches to Managing Autoimmune Cytopenias in Novel Immunological Disorders with Genetic Underpinnings Like Autoimmune Lymphoproliferative Syndrome Autoimmune lymphoproliferative syndrome: an update and review of the literature Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies Nitric oxide-driven hypoxia initiates synovial angiogenesis, hyperplasia and inflammatory lesions in mice SWEETLEAD: an in silico database of approved drugs, regulated chemicals, and herbal isolates for computer-aided drug discovery Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.Pentostatin for treatment of refractory autoimmune lymphoproliferative syndrome.Autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura in pediatric solid organ transplant recipients, report of five cases and review of the literature.Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood.Diagnosis and management of autoimmune cytopenias in childhood.Control of thrombotic thrombocytopenic purpura by sirolimus in a child with juvenile myelomonocytic leukemia and somatic N-RAS mutation.Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS).Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome Tailoring mTOR-based therapy: molecular evidence and clinical challenges.The expanding spectrum of the autoimmune lymphoproliferative syndromes Metabolic regulation of organelle homeostasis in lupus T cells Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial.Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes.Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations Advances in autoimmune lymphoproliferative syndromes.Combined Autoimmune Cytopenias Presenting in Childhood.Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children.Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles.TCF1 deficiency ameliorates autoimmune lymphoproliferative syndrome (ALPS)-like phenotypes of lpr/lpr mice.Primary Immunodeficiency Diseases: Current and Emerging Therapeutics.Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B.Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory Primitive or Secondary Autoimmune Cytopenias: a single centre experience.Induction of tolerance to factor VIII by transient co-administration with rapamycin.Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome.Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).Stabilized β-Catenin Ameliorates ALPS-Like Symptoms of B6/lpr Mice.Autoimmune lymphoproliferative syndrome: more than a FAScinating disease.Alpha beta double negative T cells in children with systemic lupus erythematosus: The relation to disease activity and characteristics.Sirolimus for the treatment of multi-resistant autoimmune haemolytic anaemia in children.

P2860

Q24623371-68C39D8E-74E1-4877-8B6F-AF236A9D52A3 Q24633207-5939195D-C78D-441B-A9BA-FE7E3F0407EE Q26799956-AFE537AA-3081-4268-9CF2-D28C3B182293 Q26825740-C968C387-0426-4206-9321-A8955DC1CFE2 Q26829652-F3F9EBD7-8183-49B7-8A6C-0935133FEFDF Q28066193-CA4B8B1C-53A4-452B-9F3C-404A80E2C19E Q28482073-B2CDAEAB-EAB3-4D90-B88F-5CEB0545093B Q28534778-AE74BDD2-5AEE-4C52-A9BD-F317CC7CC595 Q33393707-4FEE1FDA-5811-4DFE-8B46-162EB8E58833 Q33394927-BDC9E165-C5D0-4DD2-88ED-2364516CE172 Q33398417-9C03CDE5-7B74-4CE7-BE6F-CFB61B5013EE Q33404099-BB03CD0A-1A21-4D65-AAC4-7A0CE682BDA1 Q33411497-D16908A7-C747-4460-B254-DAD537985CEE Q33413641-27744C87-6BA5-41E3-A704-8B5FF681D462 Q33420245-828F61B0-5623-46A5-AF84-397C6C3EDC66 Q33944255-81D49C44-4569-4705-BE18-602078AEFECE Q34239719-82E881A3-D2C3-4572-A957-49B8924021E3 Q34294170-4FE993EA-B467-41B7-94BB-FBE970695140 Q35619447-810A46B9-4E67-4298-B64A-6B9FCE07A24A Q36177195-0310B8C3-E5C4-42C4-BA16-9995C78B5922 Q36443121-479F046E-9394-44B1-AA22-D0313313E2A0 Q37339132-BDCA8B2B-3C9A-4133-9DDC-69F895317AED Q37432231-A4A51BC1-73C6-4F9F-B8BD-870E1DD70909 Q37598141-413D0453-A773-45DB-ACEB-B2D963284304 Q37670054-BB415D0C-F6C1-4F22-AD79-B28D5172FDBA Q37859077-272F9C47-6FF4-4BB2-8413-93F9BD05827E Q38591461-AE621996-3FC0-48D4-8AEC-AD7732341959 Q38823961-BAA7EF8F-0AB3-4D54-A1B7-D8694C983507 Q39321120-7E854D41-6BC3-465F-BA1E-F5114F982C3F Q39609044-6B0D6BED-F930-4992-9D95-8E5D198078B9 Q40076704-D2DCF0B8-5810-45B7-B7F4-3B2792BA5206 Q40485786-C6B5BC0A-1D9E-4DFE-80C5-EB25F88CFA63 Q41172796-0154E97C-5ADC-4997-AA94-C3F49D90A938 Q41824863-AA0597B2-5820-40ED-A25E-054BB7C28A4B Q42325007-19B3C6C5-7A3A-435C-BF58-C06BA8158C8E Q42700395-0DED4B9F-44DC-435E-AB76-A228910CD258 Q47136733-12747257-4011-44C6-A0C2-9D529FB5A0FC Q47151016-D5C5D502-828C-4A66-8037-658D5FE627D3 Q48277630-A2472913-825E-4DE2-9B4D-C4DC04BC24FE Q50467512-02F48F6F-224A-4D6B-8368-C9577AE634AF

P2860

Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome

http://www.wikidata.org/entity/Q24650472

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Treatment with sirolimus resul ...... e lymphoproliferative syndrome

@ast

Treatment with sirolimus resul ...... e lymphoproliferative syndrome

@en

Treatment with sirolimus resul ...... e lymphoproliferative syndrome

@nl

type

label

Treatment with sirolimus resul ...... e lymphoproliferative syndrome

@ast

Treatment with sirolimus resul ...... e lymphoproliferative syndrome

@en

Treatment with sirolimus resul ...... e lymphoproliferative syndrome

@nl

prefLabel

Treatment with sirolimus resul ...... e lymphoproliferative syndrome

@ast

Treatment with sirolimus resul ...... e lymphoproliferative syndrome

@en

Treatment with sirolimus resul ...... e lymphoproliferative syndrome

@nl

P1433

Q24650472-750D7DC3-4D2D-40E5-869F-83E4C6D79FB5

P1476

Q24650472-9A9DF189-20E9-469B-ADBD-2CA26AA898DC

P2093

Q24650472-0EACE47C-DFB1-47F7-BA34-37364B722111

Q24650472-4E9D5CEE-2723-4F76-869B-28B53E7A668E

Q24650472-6FB1A0A4-BAC7-47BA-8CF1-3B5DDDD66205

Q24650472-6FC4784B-8C28-4F48-8099-05522CA4B852

Q24650472-71431ACF-1923-4C5F-B581-6AEF363F7A8A

Q24650472-763F8291-37BA-4991-9480-ED1369F27FA9

Q24650472-9343A1DD-4F5B-4F9E-90A9-C5E018B68C09

Q24650472-950261DC-7300-41B3-A163-2BDC3087945A

Q24650472-95633B90-BA23-4F02-A7B7-AE023BE36CEF

Q24650472-982767E8-1C0A-4196-B1A2-2FC8714AE46B

P2860

Q24650472-03E8F2F8-DF78-4D74-A28D-BD65045D8E3B

Q24650472-29DD520B-0FB5-452F-AEF3-5CA3FEA28639

Q24650472-404EB2CB-56C2-4BC9-8E6D-15FAA0E40077

Q24650472-414CFBB6-C13B-46F6-B9E5-33DF6C8A55EF

Q24650472-510F2D53-D019-465A-9088-B7A71F61C085

Q24650472-64411902-6B10-41B8-AECF-E26B581945AF

Q24650472-78C3F355-8777-4980-80BF-4B8A0DF133DA

Q24650472-9190757D-12BA-4734-BC14-307511663F31

Q24650472-97965348-B9D3-4753-8C7F-22BDFDA1197F

Q24650472-9DF41A63-134B-4900-A4FC-16ADAB616CAF

P304

Q24650472-AEAFB3AD-D4B5-436E-898D-DFC96547940F

P31

Q24650472-7C0B8A52-F845-4792-A986-215416D3DCD0

P356

Q24650472-DE917E76-DAC6-4F10-B70D-C8BA38D21C6A

P407

Q24650472-21B98888-1F33-4A55-80E9-944860CA52FA

P433

Q24650472-D6FEC709-4034-45AF-A7C6-162F0BF42DCB

P478

Q24650472-1FFD2233-6BEB-4A0C-A63E-945973BEC397

P577

Q24650472-4555C080-3FCA-48BC-858D-AF8790EB1588

P5875

Q24650472-206945EF-A374-4DC4-A80F-66D0DE860700

P698

Q24650472-6DB3CC3A-8F8E-4F87-AFFA-3158AE004814

P921

Q24650472-668DCACA-22B7-446C-98AD-AA8A58F87DF1

P932

Q24650472-D185A4DC-9877-4335-865E-06A6D2D4747C

P356

J.1365-2141.2009.07595.X

P1433

British Journal of Haematology

P1476

Treatment with sirolimus resul ...... e lymphoproliferative syndrome

@en

P2093

Alix Seif

http://www.w3.org/2001/XMLSchema#string

Catherine Manno

http://www.w3.org/2001/XMLSchema#string

Cecilia Sheen

http://www.w3.org/2001/XMLSchema#string

Daniel S Wechsler

http://www.w3.org/2001/XMLSchema#string

David T Teachey

http://www.w3.org/2001/XMLSchema#string

Dirk Schwabe

http://www.w3.org/2001/XMLSchema#string

Edward Attiyeh

http://www.w3.org/2001/XMLSchema#string

Eric Rappaport

http://www.w3.org/2001/XMLSchema#string

Hongming Zhuang

http://www.w3.org/2001/XMLSchema#string

Jack Bleesing

http://www.w3.org/2001/XMLSchema#string

P2860

Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)

Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome

The Fas death factor

Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival.

Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8- double-negative regulatory T cells.

Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways.

Spotlight on autoimmune lymphoproliferative syndrome.

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities.

Mammalian target of rapamycin as a target in hematological malignancies.

Targeting Notch signaling in autoimmune and lymphoproliferative disease.

P304

101-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2009.07595.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

145

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23998606

http://www.w3.org/2001/XMLSchema#string

P698

19208097

http://www.w3.org/2001/XMLSchema#string

P921

autoimmune lymphoproliferative syndrome

P932

2819393

http://www.w3.org/2001/XMLSchema#string